압타바이오

293780KOSDAQ

56.3 / 100

Reference Date: 2026-09-08

Financial Score16.0 / 40

News Sentiment21.3 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 14.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

AptaBio is a specialized pharmaceutical company developing innovative drugs based on three platform technologies: oxidative stress modulation, CAF Modulation, and aptamer-drug conjugate (Apta-DC). The company focuses on drug pipeline development, including eight therapeutic candidates, and expanded into health functional food ODM and pet care businesses through its newly established New Business Division in 2023. Key revenue streams include technology fees, reagent sales, and product sales from new business segments.

Number of Employees

45people

Average Salary

57.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

3.81Industry Average 1.200.0Point

3.2x industry avg (risky)

ROE

-32.25Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

6.63Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲473.9% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲0.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -34.8% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
압타바이오, 투자사 지분 팔아 중복상장·CB 풋옵션 해결 '일거양득'
압타바이오는 FMW 지분 매각으로 자금을 확보하고 중복상장 문제 해결과 전환사채 상환에 성공, 긍정적인 재무 전략을 보여주고 있다.
Positive
압타바이오, 황반변성 치료 '알약' 미국 임상 재개
압타바이오의 황반변성 치료제 임상 재개로 인해 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position3.0Point

52w lower range (37%)

Current 6,400Won52-week high 10,42052-week low 4,000

1-month return5.0Point

1m +14.90% (rising)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral기업설명회(IR)개최2026-09-02
Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-08-24
Neutral반기보고서 (2026.06)2026-08-14